Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Severe hypoglycemic events (SHEs) in type 2 diabetes are associated with subsequent cardiovascular (CV) event risk. We examined whether CV events were associated with subsequent SHE risk. RESEARCH DESIGN AND METHODS: Time-dependent associations between SHEs and a composite CV end point (fatal/nonfatal myocardial infarction or stroke, hospitalization for unstable angina, hospitalization for heart failure [hHF]) were examined post hoc in 14,671 TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) participants with type 2 diabetes and CV disease followed for a median of 3.0 years. RESULTS: SHEs were uncommon and unassociated with sitagliptin therapy (N = 160 [2.2%], 0.78/100 patient-years vs. N = 143 [1.9%], 0.70/100 patient-years for placebo; hazard ratio [HR] 1.12 [95% CI 0.89, 1.40], P = 0.33). Patients with (versus without) SHEs were older with longer diabetes duration, lower body weight, and lower estimated glomerular filtration rate; were more frequently women, nonwhite, and insulin treated; and more often had microalbuminuria or macroalbuminuria. Analyses adjusted for clinical factors showed SHEs were associated with increased risk of the primary composite CV end point (1.55 [1.06, 2.28], P = 0.025), all-cause death (1.83 [1.22, 2.75], P = 0.004), and CV death (1.72 [1.02, 2.87], P = 0.040). Conversely, nonfatal myocardial infarction (3.02 [1.83, 4.96], P < 0.001), nonfatal stroke (2.77 [1.36, 5.63], P = 0.005), and hHF (3.68 [2.13, 6.36], P < 0.001) were associated with increased risk of SHEs. Fully adjusted models showed no association between SHEs and subsequent CV or hHF events, but the association between CV events and subsequent SHEs remained robust. CONCLUSIONS: These findings, showing greater risk of SHEs after CV events and greater risk of CV events after SHEs, suggest a common at-risk type 2 diabetes frail patient phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A causal relationship between hypoglycaemia and adverse outcomes is not always clear as low glucose levels can be a marker of ill health.139,140”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [139]
In the citing paper
“In analyses of data from the TECOS randomized trial, which compared sitagliptin with placebo, hypoglycaemia events were independently associated with subsequent CV events, but importantly, the converse was also true.139 A non-fatal CV event was independently associated with subsequent hypoglycaemia.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [139]
In the citing paper
“Although severe hypoglycaemic events were associated with higher HF hospitalization in some but not all studies, there is no clear evidence for causality.139,140,554,568”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [139]
In the citing paper
“Recent analyses have demonstrated bi-directional associations between hypoglycaemia and CV outcomes, including HF, suggesting that this is not causal, but rather reflects underlying frailty and risk of adverse outcomes.139,140”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [139]
In the citing paper
“Recent analyses have demonstrated bi-directional associations between hypoglycaemia and CV outcomes, including HF, suggesting that this is not causal, but rather reflects underlying frailty and risk of adverse outcomes.139,140”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [139]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 4×
“duration were included due to clinical relevance, and region was included as a strata variable for consistency with the TECOS primary results article (10).”
MethodSelf-citation(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Self-citationSevere hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Self-citationZoungas, S., Arima, H., Gerstein, H. C., Holman, R. R., Woodward, M., Reaven, P., Hayward, R. A., Craven, T., Coleman, R. L., & Chalmers, J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30104-3 · Cited by 529
Self-citationHypoglycemia, Diabetes, and Cardiovascular Events
Desouza, C. V., Bolli, G. B., & Fonseca, V. (2010) · Diabetes Care · doi:10.2337/dc09-2082 · Cited by 443
Association of Hypoglycemia and Cardiac Ischemia
Desouza, C., Salazar, H., Cheong, B., Murgo, J., & Fonseca, V. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1485 · Cited by 406
Research works printed but not linked: 1
- Cavender, 2014, Major hypoglycemia is associated with cardiovascular death and hospitalization for heart failure: findings from SAVOR-TIMI 53 (Abstract), Eur Heart J, 35, 342
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationThe Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationYun, J.-S., & Ko, S.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154838 · Cited by 292
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Zinman, B., Marso, S. P., Christiansen, E., Calanna, S., Rasmussen, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-2677 · Cited by 108
“our findings differ from those of the ADVANCE and TECOS analyses, it is unclear whether our results represent a direct effect of severe hypoglycemia; hence, we cannot rule out the possibility that severe hypoglycemia is a marker of frail and vulnerable patients (14,19,21).”
BackgroundResultInfluentialSelf-citationYun, J., Park, Y., Han, K., Cha, S., Ahn, Y., & Ko, S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0909-y · Cited by 99
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Mattishent, K., & Loke, Y. K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.571568 · Cited by 69
“(40) Post-hoc analysis of RCT TECOS trial (tiral evaluating cardiovascular outcomes with sitagliptin) 14671 participants; multinational, double-blind, placebo-controlled, randomized, event-driven trial designed to assess CV safety of sitagliptin vs placebo TECOS trial Type 2 diabetes, pre-existing coronary, cardiovasc…”
BackgroundInfluentialStandl, E., Stevens, S. R., Lokhnygina, Y., Bethel, M. A., Buse, J. B., Gustavson, S. M., Maggioni, A. P., Mentz, R. J., Hernandez, A. F., & Holman, R. R. (2020) · Diabetes Care · doi:10.2337/dc19-1079 · Cited by 65
“Of note, a strong reverse association, in which nonfatal CV events were associated with a subsequent increased risk of SHEs, was demonstrated in a post hoc analysis of TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) (8).”
BackgroundResultSelf-citationHanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N., Skra, J., Valensi, P., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 59
Self-citationA1C targets should be personalized to maximize benefits while limiting risks
Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0018 · Cited by 54
“This concern seems most appropriate for those with serious CV disease, for whom the likelihood of future hypoglycemia may be increased (17).”
BackgroundSelf-citationThe double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 52
“Variations in glucose level and hyperglycaemia in children with T1DM have been associated with persistent cognitive dysfunction [41, 42] and both, hyper- and hypoglycaemia were linked to various adverse CV events [43, 44], although the relationship of severe hypoglycaemia in T2DM seems to be bi-directional [45].”
BackgroundSelf-citationMcAlister, F. A., Zheng, Y., Westerhout, C. M., Buse, J. B., Standl, E., McGuire, D. K., de Werf, F. V., Green, J. B., Armstrong, P. W., Holman, R. R., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1958 · Cited by 36
Self-citationFitchett, D., Inzucchi, S. E., Wanner, C., Mattheus, M., George, J. T., Vedin, O., Zinman, B., & Johansen, O. E. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz621 · Cited by 34
Heller, S. R., Geybels, M. S., Iqbal, A., Liu, L., Wagner, L., & Chow, E. (2021) · Diabetologia · doi:10.1007/s00125-021-05556-7 · Cited by 37
Zaccardi, F., Ling, S., Lawson, C. A., Davies, M. J., & Khunti, K. (2020) · Diabetologia · doi:10.1007/s00125-020-05223-3 · Cited by 38
Pratley, R. E., Husain, M., Lingvay, I., Pieber, T. R., Mark, T., Saevereid, H. A., Møller, D. V., Zinman, B., & the DEVOTE Study Group (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0960-8 · Cited by 25
Targets for blood glucose: What have the trials told us
Valensi, P. E., Prévost, G., Schnell, O., Standl, E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885456 · Cited by 27
“Accordingly, a relationship between non-fatal cardiovascular events and the subsequent risk of severe hypoglycaemic events was reported from a recent post-hoc analysis of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study suggesting a common at-risk T2DM frail patient phenotype.(31) Thus, prev…”
ResultSelf-citationChang, S., Chien, N., Wai, J. P. M., Chiang, C.-C., & Yu, C. (2021) · Journal of Advanced Nursing · doi:10.1111/jan.14807 · Cited by 25
Abdelhafiz, A. H., Peters, S., & Sinclair, A. J. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109085 · Cited by 24
Li, G., Zhong, S., Wang, X., & Zhuge, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1222409 · Cited by 26
“The relationship between hypoglycaemia and cardiovascular events is bidirectional in accordance with previous studies (75, 86).”
ResultAbdelhafiz, A. H., & SINCLAIR, A. J. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108144 · Cited by 23
Hypoglycaemia and its management in primary care setting
Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3332 · Cited by 21
“Severe hypoglycaemia is almost always related to insulin and sulphonylurea therapy, in both T1DM and T2DM.”
BackgroundInfluentialSelf-citationHow Significant Is Severe Hypoglycemia in Older Adults With Diabetes?
Chow, L. S., & Seaquist, E. R. (2020) · Diabetes Care · doi:10.2337/dci19-0069 · Cited by 21
Gouda, P., Zheng, S., Peters, T. M., Fudim, M., Randhawa, V. K., Ezekowitz, J. A., Mavrakanas, T. A., Giannetti, N., Tsoukas, M. A., Lópes, R. D., et al. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00527-w · Cited by 28
“Contrary to previous studies that highlighted a higher incidence of severe hypoglycemic events amongst women [43], Segar et al.”
ResultSantamarina, M. L., & Carlson, C. J. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1036-0 · Cited by 21
Malik, A. H., Yandrapalli, S., Aronow, W. S., Jain, D., Frishman, W. H., Panza, J. A., & Cooper, H. A. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000276 · Cited by 21
Long, X., Liao, S., Li, E., Pang, D., Ma, Q., Liu, S., Hu, T., & Zou, Y. (2021) · Food Science & Nutrition · doi:10.1002/fsn3.2321 · Cited by 20
“Currently, drugs are principally administered to reduce blood glucose and improve the anti- oxidative capacity of patients with diabetes (Standl et al., 2018; Wang, Wang, et al., 2018; Wang, Zhao, et al., 2018; Wu et al., 2017).”
BackgroundD’Elia, J. A., Mulla, C. M., Liu, J., & Weinrauch, L. A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.015 · Cited by 19
Obesity and its management in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Alvarez, J. A., Baker, J. C., Bruni, V., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Domenico, F. D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109045 · Cited by 21
Self-citationHeller, S. R., Lingvay, I., Marso, S. P., Philis‐Tsimikas, A., Pieber, T. R., Poulter, N. R., Pratley, R. E., HACHMANN-NIELSEN, E., Kvist, K., Lange, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14208 · Cited by 17
Self-citationMarx, N., Kolkailah, A. A., Rosenstock, J., Johansen, O. E., Cooper, M. E., Alexander, J. H., Toto, R. D., Wanner, C., Espeland, M. A., Mattheus, M., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4602 · Cited by 17
Standl, E., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108054 · Cited by 14
Self-citationLo, S., Yang, Y., Kornelius, E., Huang, J., Lai, Y., Huang, C., & Chiou, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13746 · Cited by 14
“This concept is supported by analyses from the ADVANCE trial and the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).(20) In the ADVANCE trial, the risk of a CV event was markedly attenuated after adjusting for confounding factors, suggesting that the effects of confounders were substantial.”
BackgroundResultBonadonna, R. C., Giaccari, A., Buzzetti, R., Perseghin, G., Cucinotta, D., Avogaro, A., Aimaretti, G., Larosa, M., Fanelli, C. G., & Bolli, G. B. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3304 · Cited by 17
“Minimizing the risk of even nonsevere hypoglycaemia, as in ITAS, is important to prevent long-term hypoglycaemia unawareness,(20) and the subsequent risk for severe hypoglycaemia,(21) which is associated with higher risk of cardiovascular morbidity and mortality.(22,23) Interestingly, there was no increase in body wei…”
ResultRisk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
Heller, S. R., Lingvay, I., Marso, S. P., Philis‐Tsimikas, A., Pieber, T. R., Poulter, N. R., Pratley, R. E., HACHMANN-NIELSEN, E., Kvist, K., Lange, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14049 · Cited by 15
Self-citationCardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
Self-citationZhang, J., He, X., Zhang, L., Wang, K., Chen, H., & Wu, J. H. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108493 · Cited by 14
Vilsbøll, T., Ekholm, E., JOHNSSON, E. K., García‐Sánchez, R., Dronamraju, N., Jabbour, S. A., & Lind, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13981 · Cited by 12
“Previous studies have shown an association between lower hypoglycaemia, reduced risk of cardiovascular disease and cognitive impairment, and better quality of life.(36,37) SGLT2is are associated with a beneficial cardiovascular profile.”
ResultKuo, S., Yang, C., Wu, J., & Ou, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13525 · Cited by 11
Carreira, A. S., Castro, P., Mira, F. S., Melo, M., Ribeiro, P., & Santos, L. D. C. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02112-0 · Cited by 12
“Nonetheless, increasing evidence suggests a bidirectional association between severe hypoglycaemia and cardiovascular events in type 2 diabetes, possibly explained by a common at-risk phenotype of frail patients [8, 9].”
BackgroundFadini, G. P., Frison, V., Simioni, N., Lapolla, A., Gatti, A., Bossi, A. C., Buono, A. D., Fornengo, P., Gottardo, L., Laudato, M., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012244 · Cited by 10
Standl, E., & Schnell, O. (2025) · Cells · doi:10.3390/cells14080564 · Cited by 10
“…in those on sulfonylureas), a relationship between cancer and severe hypoglycemic events has been shown, alluding to a specific multimorbid patient phenotype that needs to be recognized, as it poses challenging management issues, including de-intensification of glucose-lowering therapies [60–62].”
Self-citationFährmann, E. R., ADKINS, L. J., & Driscoll, H. K. (2021) · Diabetes Care · doi:10.2337/dc20-2757 · Cited by 10
Expanding the concept of ‘Clinical Inertia’ in diabetes
Mohan, V. (2018) · Journal of Diabetology · doi:10.4103/jod.jod_44_18 · Cited by 8
Home, P., & Itzhak, B. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001077 · Cited by 9
Shavadia, J., Zheng, Y., Green, J. B., Armstrong, P. W., Westerhout, C. M., McGuire, D. K., Cornel, J. H., Holman, R. R., & Peterson, E. D. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.09.013 · Cited by 6
Self-citationMesa, A., Giménez, M., Perea, V., Serés‐Noriega, T., Boswell, L., Blanco, J., Milad, C., Pané, A., Esmatjes, E., Vinagre, I., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3785 · Cited by 7
“31 However, the evidence regarding young individuals with T1D is unclear.”
BackgroundSeries: Cardiovascular outcome trials for diabetes drugs Sitagliptin and TECOS
Fisher, M. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.242 · Cited by 5
Positionspapier Herzinsuffizienz und Diabetes
Schütt, K. S., Aberle, J., Bauersachs, J. K., Birkenfeld, A. L., Frantz, S., Ganz, M., Jacob, S., Kellerer, M., Leschke, M., Liebetrau, C., et al. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1867-3026 · Cited by 6
Iqbal, A., Storey, R. F., & Ajjan, R. (2022) · Diabetes · doi:10.2337/dbi22-0028 · Cited by 4
“However, the direct contribution of hypoglycemia to adverse vascular outcomes is under debate, as low glucose levels can be a marker of ill health (2–5), which is supported by the bidirectional relationship between hypoglycemia and CV risk (6,7).”
BackgroundRosenstock, J., Kolkailah, A. A., McGuire, D. K., Espeland, M. A., Mattheus, M., Pfarr, E., Lund, S. S., Marx, N., & the CAROLINA Investigators (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14991 · Cited by 4
Bossi, A. C., Mori, V. D., Galeone, C., Bertola, D. P., Gaiti, M., Balini, A., Berzi, D., Forloni, F., Meregalli, G., & Turati, F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001507 · Cited by 4
Guideline Development for Medical Device Technology: Issues for Consideration
Battelino, T., Brosius, F. C., Ceriello, A., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., Lalic, N. M., Marx, N., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221093355 · Cited by 5
“142 Results from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) study confirmed this bidirectional relationship between severe hypoglycemic and cardiovascular events.”
BackgroundSelf-citationPositionspapier Herzinsuffizienz und Diabetes
Schütt, K. S., Aberle, J., Bauersachs, J. K., Birkenfeld, A. L., Frantz, S., Ganz, M., Jacob, S., Kellerer, M., Leschke, M., Liebetrau, C., et al. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00562-4 · Cited by 3
Advanced Technologies and Treatments for Diabetes 2018
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12661 · Cited by 3
Ulrich, F. S., Nielsen, M. F., NAPOLI, N., & Burden, A. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70548 · Cited by 2
“28,29 While ADA-EASD guidelines have advised limiting sulfonyl-urea use due to their lack of cardio-renal benefit and association with hypoglycaemia and weight gain, their continued use in UK primary care is plausibly driven by cost and accessibility.”
Interdisciplinary assessment and diagnostic algorithm: The role of the cardiologist
Rosano, G. M. C., Vitale, C., & Maltese, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108851 · Cited by 2
Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic Disease
Sharma, A., Razaghizad, A., Stevens, S. R., Lokhnygina, Y. V., Bakris, G. L., Green, J. B., McGuire, D. K., Lópes, R. D., Buse, J. B., Armstrong, P. W., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102598 · Cited by 1
Self-citationDipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., Strippoli, G. F., & Transplant, S. B. C. K. A. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015906.pub2 · Cited by 4
Standl, E., Ceriello, A., McGuire, D. K., Schnell, O., & Holman, R. R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02959-3 · Cited by 3
“Based on post hoc analyses of the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) [19], we described a robust bi-directional association between SHEs and CV events.”
InfluentialSelf-citationStandl, E., Green, J. B., & Holman, R. R. (2019) · Diabetes Care · doi:10.2337/dc18-2597
“Unfortunately, the authors did not acknowledge our article published earlier this year in Diabetes Care, “Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype” (2).”
BackgroundSelf-citationHypoglykämien bei Diabetes mellitus: häufig und gefährlich
Holstein, A., & Holstein, D. J. F. (2019) · Diabetes aktuell · doi:10.1055/a-1031-2237
“[4] Standl E, Stevens SR, Armstrong PW et al.”
BackgroundHanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1076-0738 · Cited by 1
“[28] Standl E, Stevens SR, Armstrong PW et al.”
BackgroundBala, C. G. (2019) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2019-0036
“These two reports suggest that the “frail” T2DM phenotype, characterized by older age, longer diabetes duration, lower glomerular filtration rate and, more frequently, non-White, insulin treated, and had prior CV or heart failure events, increased susceptibility for both SHEs and CV events [9,10].”
BackgroundMethodInfluentialRaffali, M. A., Muhammad, S., Hamid, H. A., Nawi, A., & Kamaruddin, N. (2021) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.036.01.15
Carta de Alemania: El museo del Gordo y el Flaco
Hansen, R. B. (2003) · Cuadernos hispanoamericanos
Carreira, A., Castro, P., Mira, F. S., Melo, M., Paiva, I., Ribeiro, P. F., & Santos, L. D. C. (2022) · Endocrine Abstracts · doi:10.1530/endoabs.81.yi9
Raffali, M. A. A.-F. B. M., Muhammad, S., Sukor, N., Hamid, H. A., Jyung, T. W., Govindaraju, S., Farouk, N. D., Nawi, A., Hassan, H. C., & Kamaruddin, N. (2020) · doi:10.21203/rs.3.rs-97651/v1
Kardiyovasküler Hastalıklarda Hemşirelik Rehberi
ÇİÇEKLİ, N., Kavak, Ş. N., Fidan, H. E., Aldemir, G., Özgün, Y., Sezer, G. N., Ozdemir, R., Doğruyol, A., Bahçeci, S., Çetin, A., et al. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3245
Yaşlılarda Düzenli Yapılan Boş Zaman Fiziksel Aktiviteleri ile Kırılganlık Düzeyi Arasındaki İlişki
Öztürk, N., Abacıgil, F., & Seven, O. (2025) · Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi · doi:10.46237/amusbfd.1472647
Brennan, E., Moin, A. S. M., Sathyapalan, T., Dempsey, L., Atkin, S. L., & Butler, A. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020822 · Cited by 1
“…interventions in T2D report associations between hypoglycemia and risk factors for cardiovascular outcomes [4,5], while subsequent trial follow-ups report significant associations with increased risk of cardiovascular events (macro-and microvascular) and cardiovascular-related death [6–8].”
Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
Lipska, K. J., & Inzucchi, S. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00010-0
Antihyperglycemic Medications With Proven Cardiovascular Safety
Green, J. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00014-8
Self-citation
Metadata
- Authors
- Standl, E., Stevens, S. R., Armstrong, P. W., Buse, J. B., Chan, J. C. N., Green, J. B., Lachin, J. M., Scheen, A., Travert, F., Van de Werf, F., Peterson, E. D., & Holman, R. R.
- Affiliations
- Helmholtz Munich (DE)
- Duke University (US)
- University of Alberta (CA)
- University of North Carolina at Chapel Hill (US)
- Chinese University of Hong Kong (HK)
- George Washington University (US)
- Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium
- Hôpital Bichat-Claude-Bernard (FR)
- University of Leuven, Leuven, Belgium
- University of Oxford (GB)
- Corresponding author
- Standl, Eberhard
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-01-08
- Volume
- 41
- Issue
- 3
- Pages
- 596-603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2782548982
- Cited by
- 76
- References
- 21
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 12 · 2020: 18 · 2019: 16 · 2018: 5
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- UNC Libraries
- Funders
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- severe hypoglycemia, type 2 diabetes, cardiovascular events, sitagliptin, TECOS trial, Fried frailty phenotype, cardiovascular outcomes, myocardial infarction, stroke, heart failure hospitalization, all-cause mortality, cardiovascular mortality, microalbuminuria, macroalbuminuria, estimated glomerular filtration rate, insulin-treated diabetes, SGLT2 inhibitors
- MeSH terms
- Sitagliptin Phosphate, Aged, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glomerular Filtration Rate, Hospitalization, Humans, Hypoglycemia, Insulin, Male, Risk Factors, Incidence, Proportional Hazards Models, Treatment Outcome, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.